UNSPSC 51393404: Choline theophyllinate or oxtriphylline

This classification denotes a phosphodiesterase inhibitor and bronchodilator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3K045XR58X. European Medicines Agency schedules Choline theophyllinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06220MIG. Choline theophyllinate generally arises in the molecular formula C7H7N4O2.C5H14NO.

The term CHOLINE THEOPHYLLINATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, no. 3 1962, list 4.) Choline theophyllinate or oxtriphylline bears US NLM identifiers UMLS ID C0055578 and NCI Concept Code C47645. SMILES: OCC[N](C)(C)C.O=C1N(C(=O)N(C2NC[NH]C12)C)C.

UNSPSC 51393404 Choline theophyllinate or oxtriphylline is a Commodity code that shows minimal alignment with actual state and local procurement activity in the recent records. The code nominally describes a specific pharmaceutical compound used as a bronchodilator and respiratory stimulant, yet the one recent opportunity tagged under this code—Seminole County, Florida's IFB for naloxone and drug deactivation systems—bears no relationship to choline theophyllinate or oxtriphylline. This mismatch suggests either a data-entry error in the source records or a systematic miscoding issue within the jurisdiction's procurement taxonomy. The actual goods being sought (naloxone and safe drug deactivation systems) fall into emergency response and harm-reduction product categories that are distinct from the respiratory pharmaceuticals the code nominally describes.

Seminole County released IFB 60459723LAS on June 30, 2026, with responses due July 26, 2023 (a date inconsistency in the record itself), seeking annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract includes an initial two-year term with optional one-year renewal, fixed-fee pricing, and compliance requirements including E-Verify, drug-free workplace certification, and FEMA-related federal regulations such as the Clean Air Act and Federal Water Pollution Control Act. This single opportunity provides no reliable basis for assessing the code's market activity. The absence of additional recent opportunities and the fundamental mismatch between the code's pharmaceutical scope and the naloxone/deactivation-system procurement suggest this code does not reflect genuine state and local buying patterns worth pursuing under its nominal scope.